Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor-Associated Hypertension and Vascular Disease.
Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor-Associated Hypertension and Vascular Disease.
复制标题
DOI：
10.1161/hypertensionaha.117.10271
复制
发表时间：
2018-03
期刊：
影响因子：
--
通讯作者：
Moslehi J
中科院分区：
文献类型：
--
作者：
Pandey AK;Singhi EK;Arroyo JP;Ikizler TA;Gould ER;Brown J;Beckman JA;Harrison DG;Moslehi J
e2高血压2018年2月针对> 1个激酶受体，允许更广泛的使用适应症，但脱靶效应的可能性更大。在过去十年中，VSP抑制剂已被研究作为抗癌疗法。已知实体瘤会分泌促血管生成因子，如果受到抑制，可减缓和限制肿瘤生长。9，10贝伐单抗最初于2004年被批准作为转移性结直肠癌标准化疗的附加治疗;因为它已被用作其他几种实体恶性肿瘤的抗肿瘤治疗，包括肾细胞癌，非小细胞肺癌和多形性胶质母细胞瘤。VEGFR TKI目前适用于肾细胞癌、肝细胞癌、结直肠癌、胃肠道间质瘤、胰腺神经内分泌肿瘤、软组织肉瘤和甲状腺髓样癌。除了用于癌症治疗外，VSP抑制剂还常用于视网膜增殖性疾病;然而，眼内注射的毒性特征与全身给药相比可能显著不同。
e2 Hypertension February 2018 target> 1 kinase receptor allowing for a broader indication for use but with a greater potential for off-target effects. VSP inhibitors have been investigated in the last decade as anticancer therapies. Solid tumors were known to secrete a proangiogenic factor, which, if inhibited, could slow and restrict tumor growth. 9, 10 Bevacizumab was initially approved in 2004 as an add-on to standard chemotherapy for metastatic colorectal cancer; because it has been used as adjunctive therapy in several other solid malignancies, including renal cell carcinoma, nonsmall cell lung cancer, and glioblastoma multiforme. The VEGFR TKIs are currently indicated for use in renal cell carcinoma, hepatocellular carcinoma, colorectal cancer, gastrointestinal stromal tumor, pancreatic neuroendocrine tumor, soft tissue sarcomas, and medullary thyroid cancer. In addition to their use in cancer treatment, VSP inhibitors are also commonly used in proliferative diseases of the retina; however, the toxicity profile with intraocular injection likely differs significantly compared with systemic delivery.